Report Id: SNS/HC/1074 | May 2022 | Region: Global | 125 Pages
Report Scope & Overview:
The Single-Use Bioreactors Market Size was valued at USD 2.57 billion in 2021 and is expected to reach USD 7.83 billion by 2028, and grow at a CAGR of 17.2% over the forecast period 2022-2028. Due to their great efficiency, single-use bioreactors are ideal for the manufacturing of biopharmaceutical products. They have advanced significantly in recent years as a result of firms' tireless attempts to disseminate goods. They may be seen working on sensor systems, designs, stirring mechanisms, and single-use bioreactor film technology.
The growing acceptance of single-use bioreactors among small businesses and start-ups, reduced automation complexity, ease of agriculture of marine organisms, reduced energy and water consumption, the growing biologics market, technological advancements in single-use bioreactors, and the growth of biopharmaceutical research and development are all factors driving the market forward. However, obstacles such as single-use bioreactor administration challenges and worries about leachables and extractables are projected to stymie market expansion in the foreseeable term.
Furthermore, license expiration and emerging markets are projected to generate favorable new chances for the single-use bioreactors market to flourish. Despite this, one of the main difficulties for the growth of single-use bioreactors during the projection period is projected to be the desire for improved single-use sensors and the standardization of single-use layouts.
Increase in demand for biopharmaceutical
A significant portion of small- and mid-scale biopharmaceutical production
Emerging countries market
Availability of less severe regulatory rules
Low-cost trained workforce
Availability of sensors that are dependable, accurate, and affordable.
The quality of available sensors does not meet GMP requirements.
IMPACT OF COVID-19
Coronavirus is a recently distinguished novel Corona that causes an irresistible affliction. Coronavirus, which was generally obscure until the episode in Wuhan, China, in December 2019, has gone from a local issue to a worldwide pandemic in only half a month. In light of the novel COVID pandemic, numerous biopharmaceutical organizations are quickly creating antibodies. Because of the novel COVID pandemic, numerous biopharmaceutical organizations are quickly creating antibodies. Moderna Therapeutics, for example, has a messenger RNA vaccine in Phase I studies, Inovio Pharmaceuticals has a DNA vaccine in human trials, and Novavax is working on a vaccine based on its recombination protein nanoparticle platform. If these programs have passed their trials, single-use equipment and systems will be used to support clinical and commercial manufacturing platforms.
In the quest to produce a coronavirus vaccine, many prominent single-use bioreactor manufacturers are presently collaborating with businesses that have a vaccine in development or are already in clinical trials. Sartorius, for instance, has supported CanSino Biologics Inc. what's more, Maj. Gen. Chen Wei's group at China's Academy of Military Medical Sciences' Institute of Bioengineering in the formation of the primary antibody up-and-comer against the new COVID SARS-CoV-2 to enter clinical preliminaries. Here and there, this affects the SUB market. In the bioprocessing solutions market, the impact of the coronavirus crisis on supply chains, manufacturing, and shipments to consumers has been manageable until now. Predictability in the short and medium-term is severely limited and has little impact.
The single-use bioreactors market is disengaged into three classes: single-use bioreactors structure, single-use media pack, and single-use filtration get-togethers.
Stirred tank single-use bioreactors, bubble column single-use bioreactors, and wave-induced single-use bioreactors are the three types of single-use bioreactors available.
By Molecule Type:
The single-use bioreactors market is divided into monoclonal antibodies (MAbs), vaccines, stem cells, gene-modified cells, and other molecules.
By Cell Type:
The single-use bioreactors market is divided into mammalian cells, bacterium cells, yeast cells, and other cells based on cell type.
The single-use bioreactors market is divided into three categories,
research and development, process development, and bioproduction.
Thermo Fisher Scientific, Danaher, Sartorius Stedim Biotech, Merck KgaA, Getinge AB, Celltainer Biotech BV, Eppendorf AG, PBS Biotech Inc., Solida Biotech GmbH, Cellexus, Distek Inc., Able Corporation & Biott Corporation, ABEC, G&G Technologies Inc., Satake Chemical Equipment Mfg Ltd., bbi-biotech GmbH, Stobbe Pharma GmbH.
KEY MARKET SEGMENTS:
Single-use Bioreactor Systems
Single-use Filtration Assemblies
Single-use Media Bags
By type of cell
Other Cells (Insect and plant cells)
By Molecule Type
Research and Development (R&D)
By End User
Pharmaceutical & Biopharmaceutical Companies
Academic & Research Institutes
CROs & CMOs
The market for single-use bioreactors was dominated by North America, followed by Europe. A significant portion of the North American topographical fragment can be ascribed to the presence of a deep-rooted biopharmaceutical industry as well as significant members in the single-use bioreactors market.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 2.57 Billion|
|Market Size by 2028||US$ 7.83 Billion|
|CAGR||CAGR of 17.2% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Product (Single-use Bioreactor Systems, Single-use Filtration Assemblies, Single-use Media Bags, Other)
• By Type (Stirred-tank SUBs, Bubble-column SUBs, Wave-induced SUBs, Other SUBs )
• By Type of Cell (Mammalian Cells, Yeast Cells, Bacterial Cells, Other Cells)
• By Molecule Type (Monoclonal Antibodies, Gene-modified cells, Vaccines, Stem Cells, Other Molecules)
• By Application (R&D, Bioproduction, Process Development)
• By End User (Pharmaceutical & Biopharmaceutical Companies, Academic & Research Institutes, CROs & CMOs)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Thermo Fisher Scientific, Danaher, Sartorius Stedim Biotech, Merck KgaA, Getinge AB, Celltainer Biotech BV, Eppendorf AG, PBS Biotech Inc., Solida Biotech GmbH, Cellexus, Distek Inc., Able Corporation & Biott Corporation, ABEC, G&G Technologies Inc., Satake Chemical Equipment Mfg Ltd., bbi-biotech GmbH, Stobbe Pharma GmbH.|
|DRIVERS||• Increase in demand for biopharmaceutical
• A significant portion of small- and mid-scale biopharmaceutical production
• Single-use system
|OPPORTUNITIES||• Emerging countries market
• Availability of less severe regulatory rules
• Low-cost trained workforce.
Frequently Asked Questions (FAQ) :
The single-Use Bioreactors market is expected to grow at a CAGR of 17.2%.
The availability of sensors that are dependable, accurate, and affordable are the restraints of the market.
Single-Use Bioreactors Market is divided into two segments and they are by Product, By type, by type of cell, by molecule, by application, and by End-user
The market for single-use bioreactors was dominated by North America, followed by Europe.
Manufacturer and service provider, research institutes, university, and private libraries, suppliers, and distributors.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of Ukraine Russia War
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Single-Use Bioreactors Market Segmentation, by Product
8.1 Single-use Bioreactor Systems
8.2 Single-use Filtration Assemblies
8.3 Single-use Media Bags
9. Single-Use Bioreactors Market Segmentation, by Type
9.1 Stirred-tank SUBs
9.2 Bubble-column SUBs
9.3 Wave-induced SUBs
10. Single-Use Bioreactors Market Segmentation by Type of Cell
10.1 Mammalian Cells
10.2 Yeast Cells
10.3 Bacterial Cells
11. Single-Use Bioreactors Market Segmentation, by Molecule Type
11.1 Monoclonal Antibodies
11.2 Gene-modified cells
11.4 Stem Cells
12. Single-Use Bioreactors Market Segmentation by Application
12.1 Research and Development (R&D)
12.3 Process Development
13. Single-Use Bioreactors Market Segmentation by End User
13.1 Pharmaceutical & Biopharmaceutical Companies
13.2 Academic & Research Institutes
13.3 CROs & CMOs
14. Regional Analysis
14.2 North America
14.3.6 The Netherlands
14.3.7 Rest of Europe
14.4.2 South Korea
14.4.6 Rest of Asia-Pacific
14.5 The Middle East & Africa
14.5.3 South Africa
14.6 Latin America
14.6.3 Rest of Latin America
15. Company Profiles
15.1 Thermo Fisher Scientific
15.1.2 Products/ Services Offered
15.1.3 SWOT Analysis
15.1.4 The SNS view
15.3 Sartorius Stedim Biotech
15.4 Merck KgaA
15.5 Getinge AB
15.6 Celltainer Biotech BV
15.7 Eppendorf AG
15.8 PBS Biotech Inc
15.9 Solida Biotech GmbH
15.10 Cellexus, Distek Inc
15.11 Able Corporation & Biott Corporation
15.15 G&G Technologies Inc
15.15 Satake Chemical Equipment Mfg., Ltd
15.15 bbi-biotech GmbH
15.16 Stobbe Pharma GmbH
16. Competitive Landscape
16.1 Competitive Benchmark
16.2 Market Share analysis
16.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of a good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach a stage wherein we can provide our clients best and most accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research as the name suggests is a research process wherein, we collect data through readily available information. In this process, we use various paid and unpaid databases to which our team has access and gather data through the same. This includes examining listed companies’ annual reports, Journals, SEC filling, etc. Apart from this, our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various universities as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content-specific facts that can be sued to solve specific problems. Since the collected data is fresh and first-hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply sides of the industry to make sure we land an accurate judgment and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses, and observation of on-field participants. The below-mentioned chart should give a better understanding of part 1 of the primary interview.
Part 2: In this part of the primary research the data collected via secondary research and part 1 of the primary research is validated with the interviews with individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence center, our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real-time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but is not limited to getting rid of the many typos, duplication of numbers, or missing any important information. The people involved in this process include technical content writers, research heads, and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.